Castle Biosciences Inc (CSTL) — Capital Reinvestment Ratio
Latest as of December 2025:
0.27x
Castle Biosciences Inc (CSTL) has a Capital Reinvestment Ratio of 0.27x as of December 2025, meaning it reinvests 0% of its operating cash flow ($26.93 Million) in capital expenditures ($7.18 Million). See cash generation quality of Castle Biosciences Inc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.27x
Capex / Operating Cash Flow
Operating Cash Flow
$26.93 Million
USD
Capital Expenditures
$7.18 Million
USD
Data as of
Dec 2025
Most recent filing
Castle Biosciences Inc Capital Reinvestment Ratio (2019–2025)
This chart tracks Castle Biosciences Inc's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Castle Biosciences Inc (2019–2025)
Year-by-year Capital Reinvestment Ratio for Castle Biosciences Inc from 2019 to 2025. For live market cap and broader valuation context, see Castle Biosciences Inc (CSTL) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.56x | $64.35 Million | $36.02 Million | ▲ +28.2% |
| 2024 | 0.44x | $64.87 Million | $28.33 Million | ▼ -9.3% |
| 2020 | 0.48x | $9.87 Million | $4.75 Million | ▲ +260.6% |
| 2019 | 0.13x | $7.01 Million | $937.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow